Breaking News, Collaborations & Alliances

Aptamer Group and PinotBio Extend Collaboration Agreement

Will develop four new Optimer-drug conjugates for use as precision chemotherapeutics.

Author Image

By: Charlie Sternberg

Associate Editor

Aptamer Group plc, a developer of novel Optimer binders to enable innovation in the life sciences industry, has extended its collaboration agreement with PinotBio, a clinical-stage oncology-focused biotechnology company, to develop four new Optimer-drug conjugates for use as precision chemotherapeutics.   The partnership was first initiated in June 2021 targeting haematological cancers. The first phase of the project demonstrating the viability of combining Optimer technology with PinotBio&#82...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters